Gedea receives funding from Horizon 2020

Gedea has been granted SEK 500,000 in appropriations from the SME Instrument phase 1 program within the EU Horizon 2020 framework program. The Horizon 2020 program is competitive and only a few percent of all grant applications are granted.

"The grant from Horizon 2020 is both an important funding that enables us to maintain momentum and also an acknowledgement of the qualities of the company. We are very proud to receive the grant in such tough competition, says CEO Annette Säfholm.

Gedea Biotech is a member of SmiLe Incubator, a life science business incubator that helps entrepreneurs to commercialize their ideas by offering business advisory services, laboratories and network. Gedea Biotech is also a portfolio company of LU Holding, the holding company of Lund University. www.smileincubator.life   www.innovation.lu.se

About Horizon 2020: Horizon 2020 is the EU's largest research and innovation program with nearly 80 billion euros in funding, available for 7 years (2014-2020). The program emphasizes high-quality science, industrial management and meeting social challenges. The goal is to ensure that Europe produces world-class science, removes barriers to innovation and facilitates the public and private sector to work together for innovation.

About Gedea Biotech: Gedea Biotech develops pHyph, an antibiotic drug, safe and effective treatment of vaginal infections. Vaginal infections affect at least 400 million women every year worldwide and the market is worth over $ 1.5 billion. 67% of women with a vaginal infection choose an ineffective treatment because they do not know if it is a fungal or bacterial infection. pHyph will be the only treatment on the market targeting both bacterial and fungal vaginal infections, thus reducing the risk of choosing wrong treatment. www.gedeabiotch.com

For information contact: Annette Säfholm CEO, +46 (0)73 4000433, annette.safholm@gedeabiotech.com